Xcout Intel
ALZHEON, INC.
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
Subscribe to see ALZHEON, INC.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ALZHEON, INC. at a glance
ALZHEON, INC. is a biotechnology company headquartered in United States, founded in 2013. Its most recent funding round raised $78.8M in August 2026. Xcout tracks 13 named people at ALZHEON, INC., including Martin Tolar, M.D., Ph.D. (President and Chief Executive Officer).
ALZHEON, INC. leadership
- Martin Tolar, M.D., Ph.D.President and Chief Executive Officer
- Adem AlbayrakExecutive Officer
- Aidan Power, MRCPsychExecutive Officer
- John Hey, Ph.D.Executive Officer
- Kenneth MaceExecutive Officer
- Martin Tolar, M.D., Ph.D.Executive Officer
7 more named people on record for ALZHEON, INC., with roles, board committees and tenure — see the full roster →
ALZHEON, INC. funding rounds
The 4 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $78.8M | — | |
| Series E | $125M | 1 named | |
| Series E | $100M | 1 named | |
| SEC Form D filing | $126.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent ALZHEON, INC. news
- FundingPrivate placement (Form D)
Investors
ALZHEON, INC. competitors
A few of ALZHEON, INC.'s closest competitors — see the full list of competitors and alternatives →
Alzinova AB is a Swedish clinical-stage biopharmaceutical company that develops disease-modifying treatments and vaccines targeting Alzheimer's disease. Utilizing its proprietary AβCC Peptide technology, the company focuses on creating therapeutics for Alzheimer's patients to address high unmet medical needs in neurodegeneration.
Cognition Therapeutics, Inc. is a public, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company develops therapies designed to protect neurons and advance treatments for patients living with age-related neurodegenerative diseases.
Cortexyme, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutics for major degenerative disorders.
AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company founded in 2011 and headquartered in Boston, Massachusetts. The company focuses on developing novel treatments for devastating neurological conditions.
Avraham Pharmaceuticals Ltd. is a biotechnology company headquartered in Yavneh, Israel, founded in 2010. The company develops novel small molecule drugs and multi-functional drug substances, such as ladostigil, aimed at the treatment and prevention of neurodegenerative disorders and mild cognitive impairment.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Get ALZHEON, INC.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ALZHEON, INC. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 13 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access